Recent Analysts’ Ratings Changes for Omnicell (OMCL)

A number of firms have modified their ratings and price targets on shares of Omnicell (NASDAQ: OMCL) recently:

• 10/19/2024 – Omnicell was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 10/14/2024 – Omnicell had its price target raised by analysts at Wells Fargo & Company from $30.00 to $41.00. They now have an “equal weight” rating on the stock.
• 10/10/2024 – Omnicell was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 10/9/2024 – Omnicell had its “buy” rating reaffirmed by analysts at Benchmark Co.. They now have a $48.00 price target on the stock.
• 9/19/2024 – Omnicell was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 9/11/2024 – Omnicell was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 8/23/2024 – Omnicell had its price target raised by analysts at JPMorgan Chase & Co. from $26.00 to $37.00. They now have a “neutral” rating on the stock.

Omnicell Trading Down 1.5 %

NASDAQ OMCL traded down $0.63 during trading hours on Monday, hitting $40.47. 385,915 shares of the company’s stock were exchanged, compared to its average volume of 518,781. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -87.98, a PEG ratio of 47.11 and a beta of 0.83. The stock has a 50-day simple moving average of $43.22 and a 200 day simple moving average of $34.33. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $45.84.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. Omnicell’s revenue for the quarter was down 7.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.29 EPS. On average, equities analysts forecast that Omnicell, Inc. will post 0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. Vanguard Group Inc. grew its position in Omnicell by 8.5% in the 4th quarter. Vanguard Group Inc. now owns 5,571,420 shares of the company’s stock valued at $209,653,000 after purchasing an additional 434,336 shares during the period. Counterpoint Mutual Funds LLC acquired a new position in shares of Omnicell during the first quarter valued at about $300,000. Diversified Trust Co grew its holdings in shares of Omnicell by 18.5% during the first quarter. Diversified Trust Co now owns 14,870 shares of the company’s stock valued at $435,000 after buying an additional 2,326 shares during the last quarter. Tributary Capital Management LLC increased its position in shares of Omnicell by 4.0% during the first quarter. Tributary Capital Management LLC now owns 315,158 shares of the company’s stock worth $9,212,000 after acquiring an additional 12,243 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its position in Omnicell by 3.9% in the 1st quarter. Principal Financial Group Inc. now owns 264,083 shares of the company’s stock valued at $7,719,000 after acquiring an additional 9,944 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.